In precision oncology, two major strategies are being pursued for predicting clinically
relevant tumour behaviours, such as treatment response and emergence of drug resistance …

Patient-derived xenograft (PDX) models are used as powerful tools for understanding
cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus …

Abstract Development of candidate cancer treatments is a resource-intensive process, with
the research community continuing to investigate options beyond static genomic …

Cancer frequency and prevalence have been increasing in the past decades, with
devastating impacts on patients and their families. Despite the great advances in targeted …

Establishing appropriate preclinical models is essential for cancer research. Evidence
suggests that cancer is a highly heterogeneous disease. This follows the growing use of …

The ever-changing nature of cancer poses the most difficult challenge oncologists face
today. Cancer's remarkable adaptability has inspired many to work toward understanding …

Background In the era of personalized medicine, the establishment of preclinical models of
cancer that faithfully recapitulate original tumors is essential to potentially guide clinical …

Hepatoblastoma (HB) is the most common primary liver malignancy of childhood, and
molecular investigations are limited and effective treatment options for chemoresistant …

Studies to date have not resolved how diverse transcriptional programs contribute to the
intratumoral heterogeneity of small cell lung carcinoma (SCLC), an aggressive tumor …

Recent developments in pre-clinical screening tools, that more reliably predict the clinical
effects and adverse events of candidate therapeutic agents, has ushered in a new era of …